Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Dr. Harry Spiera Retires after 60 Years in Rheumatology

Kurt Ullman  |  Issue: April 2018  |  April 26, 2018

In all of medicine, increased emphasis is being placed on technology and the use of guidelines and algorithms in responding to disease. Although rheumatology has certainly participated in these changes, the subspecialty still involves a large clinical component.

SLE Lupus Foundation & His Office Couch

Dr. Harry Spiera’s patient-centered outlook during his 40+ year tenure as chief of rheumatology at Mount Sinai Hospital in New York City also put him at the inception of what grew to be major players in education, research and advocacy.
“The SLE Lupus Foundation basically started on the couch in my office,” says Dr. Spiera. “Susan Golick was a young patient of mine with the disease. From a few women getting together in their living rooms, it evolved into the Lupus Research Alliance of today. The Alliance supports education, research and publicity to more widely spread knowledge of the disease.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Changes in Education

Dr. Harry Spiera says that rheumatology has also matured in the education of physicians, both in the subspecialty and during medical school. It used to be that exposure to rheuma­tolgy in medical schools consisted of one or two lectures. This was despite the fact that rheumatic diseases were some of the most common. Now, medical students have a much greater depth of education on these diseases.

“When I started my fellowship training, there were no more than 100 or 200 fellows in the entire U.S,” he noted. “Now, there are more than 70 major programs.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Harry Spiera’s fellowship was at Columbia University under Charles Christian, MD, one of the great leaders in the field.

“Those that mentored me were important,” says Dr. Harry Spiera. “When someone is a fellow, it is a close relationship between them and their director. Most fellows, especially in the early years, became heads of their own divisions. It was a very exciting and challenging experience.”

Dr. Harry Spiera was in Dr. Christian’s first group of fellows. Dr. Robert Spiera was in the last.

Trained Rheumatology’s Leaders

Dr. Harry Spiera contributed to the training of several generations of rheumatologist. It has made an impact on many active in the specialty.

“Almost every conference I attend, I am approached by somebody who says Dad was one of their most important influences as a student or a resident,” says Dr. Robert Spiera. “Many of the leaders in rheumatology today were inspired by him. This is a critical part of his educational legacy.

Page: 1 2 3 | Single Page
Share: 

Filed under:Profiles Tagged with:Dr. Harry SpieraPolymyalgia RheumaticaSLE Lupus Foundation

Related Articles

    Two Inflammatory Conditions—Polymyalgia Rheumatica and Giant Cell Arteritis—Share Clinical Connection

    March 1, 2013

    Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) have common clinical and epidemiologic links, but they need not occur synchronously

    New Findings for Polymyalgia Rheumatica & Osteoarthritis

    December 1, 2022

    The Plenary III Session reviewed the results of the SAPHYR trial of sarilumab in PMR patients, as well as the WE-CAN study on the impact of a community-level diet & exercise program on knee pain in patients with knee osteoarthritis.

    Polymyalgia Rheumatica: New Tricks for an Old Disease

    January 29, 2024

    Originally posted Feb. 13, 2023; reposted in conjunction with publication of the PMR supplement to the February 2024 issue of The Rheumatologist. PHILADELPHIA—Polymyalgia rheumatica (PMR) is a chronic inflammatory condition that almost exclusively affects individuals older than 50.1 First described in 1888, PMR has been a recognized rheumatic disease since at least 1957. Diagnosing the…

    Permanent Vision Loss in Late Giant Cell Arteritis

    October 18, 2018

    Patients with polymyalgia rheumatica (PMR) or peripheral arthritis may require extra vigilance during treatment because of a suspected link to giant cell arteritis (GCA) and, potentially, permanent vision loss. “Development of giant cell arteritis after treating polymyalgia or peripheral arthritis: a retrospective case-control study,” a March 2018 study published in The Journal of Rheumatology, suggests…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences